This Antibody was verified by Knockdown to ensure that the antibody binds to the antigen stated. View Details
Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
CHK1 (CHEK1) is a kinase that phosphorylates cdc25, an important phosphatase in cell cycle control, particularly for entry into mitosis. CHK1 can also phosphorylate p53 at Ser20 in vitro. Cell cycle events are regulated by the sequential activation and deactivation of cyclin dependent kinases (Cdks) and by proteolysis of cyclins. CHK1 is involved in these processes as regulators of Cdks. CHK1 function as an essential component in the G2 DNA damage checkpoint by phosphorylating Cdc25C in response to DNA damage. Phosphorylation inhibits Cdc25C activity, thereby blocking mitosis. Cdc25A, Cdc25B and Cdc25C protein tyrosine phosphatases function as mitotic activators by dephosphorylating Cdc2 p34 on regulatory tyrosine residues. CHK1 can phosphorylate Wee 1 in vitro, providing evidence that the hyperphosphorylated form of Wee 1, seen in cells delayed by CHK1 overexpression, is due to phosphorylation by CHK1. CHK1 is phosphorylated on Serine 345 (S345) in response to UV, IR and hydroxyurea (HU). CHK1 plays an essential role in the mammalian DNA damage checkpoint, embryonic development and tumor suppression. Further, CHK1 is a key mediator in the DNA damage-induced checkpoint network. CHK1 is an evolutionarily conserved protein kinase that functions to ensure genomic integrity upon genotoxic stress. When the G2 or S checkpoint is abrogated by the inhibition of CHK1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase. Thus, CHK1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: Cell cycle checkpoint kinase; Checkpoint kinase-1; Checkpoint, S. pombe, homolog of, 1; CHK1 checkpoint homolog; Chk1-S; homolog of Chk1-S; HRD1 Protein; Serine/threonine-protein kinase Chk1
Gene Aliases: CHEK1; CHK1
UniProt ID: (Human) O14757
Entrez Gene ID: (Human) 1111